PLUR

Pluristem Therapeutics Inc. (PSTI) - 10-Q Summary

Business Context and Reporting Period

Company: Pluristem Therapeutics Inc. (a development stage company)

Reporting Period: Nine months ended March 31, 2011 (Unaudited)

Business Overview: The Company is a bio-therapeutics firm developing non-personalized (allogeneic) cell therapy products derived from human placenta. Its primary product in development is PLX-PAD, intended for the treatment of peripheral artery disease (PAD) and critical limb ischemia (CLI). The Company has not generated any revenues since inception and relies on equity financings and government grants to fund operations.

Key Financial Metrics

Note: All figures in U.S. Dollars in thousands, except per share data.

Material Changes vs. Prior Period

• Liquidity Surge: Cash and cash equivalents increased from $1,583 (June 30, 2010) to $44,866 (March 31, 2011), a net increase of $43,283. This was driven primarily by financing activities.
• Financing Activities: Net cash provided by financing activities was $46,624, compared to $3,607 in the prior year. This includes approximately $38 million from a February 2011 public offering and $5 million from an October 2010 private placement.
• Expense Growth:
  • R&D Expenses (Net): Increased 25% to $4,123 (from $3,304), driven by increased salaries, lab materials, and stock-based compensation, partially offset by a $244 U.S. government grant.
  • G&A Expenses: Increased 31% to $3,154 (from $2,413), primarily due to a $720 increase in stock-based compensation.
• Financial Income: Turned positive to $154 (from $6 income in prior year) due to interest income on higher cash balances and exchange rate adjustments.
• Share Count: Weighted average shares outstanding increased significantly to 27,894,392 (from 16,637,335) due to recent equity offerings and warrant exercises.

Outlook, Risks, and Management Commentary

• Capital Resources: Management believes current cash resources, combined with approved grants from the Israeli Office of the Chief Scientist (OCS), are sufficient to fund operations until at least the end of calendar year 2013.
• Product Development: The Company successfully completed a scientific advisory process with the FDA and EMA for PLX-PAD. Phase I clinical trial data (announced April 2011) suggests safety and potential efficacy in reducing amputations for CLI patients. The Company plans to file for Phase II/III approval.
• Revenue Expectations: The Company does not expect to generate product revenues in the next 12 months. Products are not expected to be ready for sale for at least three years.
• Risks:
  • Continued operating losses and negative cash flows from operations.
  • Dependence on future equity financings, which may result in significant dilution to existing shareholders.
  • Uncertainty regarding the approval of future OCS grants.
  • Regulatory risks associated with clinical trials and product approval.
• Unusual Items: The Company received a $244 cash grant from the U.S. government's Qualifying Therapeutic Discovery Project (QTDP) in February 2011, recorded as a reduction of R&D expenses.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $44.9 million cash balance against the estimated $9 million annual operating burn rate to confirm the 2013 liquidity timeline.
• Dilution Impact: Review the terms of the February 2011 offering and outstanding warrants (16.7 million warrants and 2.5 million options outstanding) to assess potential future dilution.
• Grant Dependency: Confirm the status of the application for the sixth-year OCS grant filed in March 2011, as future funding is contingent on this approval.
• Clinical Milestones: Monitor the publication of full Phase I clinical trial results and the regulatory filing status for Phase II/III studies with the FDA and EMA.
• Stock-Based Compensation: Analyze the trend of non-cash stock-based compensation expenses ($2.3 million in the nine-month period) as a significant driver of reported losses.